We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Blood-Based Biomarker Predicts Onset of Symptomatic Alzheimer’s Disease

By LabMedica International staff writers
Posted on 16 Sep 2021
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, starting with a preclinical phase of normal cognition lasting approximately two decades. More...
The formal diagnosis of AD dementia, relies on neuropsychological tests further confirmed by brain imaging and cerebrospinal fluid (CSF) sampling.

The pathogenic features of AD that have an onset in the preclinical phase may allow identification of such early blood-based biomarkers. By eliciting compensatory responses, these early pathogenic changes were found to initially prevent the increase in reactive oxygen and nitrogen species (ROS/RNS) through activation of antioxidant mechanisms.

Scientists at the University of Brescia (Brescia, Italy) and their colleagues collected blood samples from 482 subjects aged between 60 and 85 years who did not present specific comorbidities (uncontrolled diabetes, vascular disease, severe depression, or psychiatric illnesses) and were included in a retrospective study collecting a total of 515 blood samples from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study by applying a consecutive sampling approach.

The team performed immunoprecipitation (IP) followed by liquid chromatography (LC) tandem mass spectrometry (MS/MS) and protein sequencing in plasma samples from the AIBL study identified the clinically relevant AZ 284 peptide (AlzoSure Predict test, Diadem, Brescia, Italy), representing a measure of the U-p53 conformational variant (U-p53AZ). Based on U-p53AZ quantification via IP/LC electrospray ionization-coupled MS/MS (Thermo Scientific EASY-nLC 1000 HPLC system, coupled to a Thermo Fisher Scientific EASYSpray source, Waltham MA, USA), supported by an analytical nanoflow column system. The predictive performance of U-p53AZ was assessed and compared with amyloid load as measured by amyloid β-positron emission tomography (Aβ-PET). Its predictive performance was determined at 36, 54, 72 and 90 months.

The investigators reported that U-p53AZ was able to identify individuals with AD dementia with an area under the receiver operating characteristic curve (AUC) of 99%. U-p53AZ outperformed the conventional Aβ-PET measures in predicting the onset of AD dementia both from preclinical (AUC=98%) and prodromal stages (AUC=89%), even 90 months prior to onset (AUC=99%). Additionally, the estimated predictive performance of U-p53AZ was superior (AUC ≥98%) to other risk factors (i.e., gender, Aβ-PET and APOE ε4 allele status) in identifying individuals at high risk for progression to AD.

The authors concluded that their findings support use of U-p53AZ as blood-based biomarker predicting if individuals, at both asymptomatic and MCI stages, would progress to AD at least six years prior to the onset of clinical AD dementia. The study was published on August 25, 2021 in the journal medRxiv.

Related Links:
University of Brescia
Diadem
Thermo Fisher Scientific



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Portable Electronic Pipette
Mini 96
Clinical Chemistry System
P780
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Impaired vascular function in patients with chronic kidney disease (A K Grotle et al., Am J Physiol Renal Physiol (2025). DOI: 10.1152/ajprenal.00158.2025)

Kidney Disease Blood Marker Could Also Identify Cardiovascular Problems

Chronic kidney disease (CKD) affects millions worldwide and is strongly linked to cardiovascular complications rather than kidney failure itself. Patients with CKD often experience vascular dysfunction... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.